西甲硅油(Simethicone) - 在研适应症：腹部膨胀，胃肠胀气_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Imonogas、simeticone

靶点-

作用方式-

作用机制-

治疗领域

其他疾病

在研适应症

腹部膨胀胃肠胀气

非在研适应症

腹痛消化道出血肠易激综合征

原研机构-

在研机构

Haleon Australia Pty Ltd.BERLIN-CHEMIE AG

非在研机构

Abbott Laboratories

Mayo Clinic

McNeil AB

最高研发阶段批准上市

首次获批日期

美国 (1952-01-01),

腹部膨胀胃肠胀气

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

关联

64

项与西甲硅油相关的临床试验

NCT06812832

/ Not yet recruiting临床4期

Simethicone as Part of an Enhanced Recovery After Surgery (ERAS) Protocol

By conducting this study, we hope to assess if simethicone (also known as Gas Relief or GasX) has an effect on improving gas pain and bloating specifically in patients undergoing foregut procedures to include bariatric procedures (sleeve gastrectomy, Roux-en-Y gastric bypass), hiatal hernia, and gastric surgery.
The purpose of this research is to gather information on the safety and effectiveness of simethicone. Simethicone (more commonly known as Gas Relief or Gas-X) relieves pressure, bloating, and fullness commonly referred to as gas. It is FDA approved. The use of this medication in this research study is consistent with labeling indications.

开始日期2025-03-01

申办/合作机构

Madigan Army Medical Center

ChiCTR2400091746

/ Suspended临床4期IIT

Efficacy of simethicone in the treatment of abdominal distension after colonoscopy: a multi-center, single-blinded, randomized controlled study

开始日期2024-11-01

申办/合作机构

复旦大学附属中山医院

CTRI/2024/10/074635

/ Not yet recruiting临床4期IIT

Effectiveness of N acetyl cysteine and Simethicone to improve mucosal visibility during GI endoscopy-An interventional study - NA

开始日期2024-10-09

申办/合作机构-

100 项与西甲硅油相关的临床结果

登录后查看更多信息

100 项与西甲硅油相关的转化医学

登录后查看更多信息

100 项与西甲硅油相关的专利（医药）

登录后查看更多信息

360

项与西甲硅油相关的文献（医药）

2025-03-01·Digestive and Liver Disease

Comparative efficacy of different bowel preparations for colonoscopy: A network meta-analysis.

Review

作者: Facciorusso, A ; Repici, A ; Di Mitri, R ; Vitello, A ; Mocciaro, F ; Hassan, C ; Vassallo, R ; Amata, M ; Maida, M ; Ramai, D ; Fabbri, A ; Marasco, G ; Fuccio, L

BACKGROUND AND AIMSThe quality of a colonoscopy is heavily reliant on the effectiveness of bowel cleansing. Various cleansing solutions are currently available, but their comparative efficacy remains uncertain. This systematic review and network meta-analysis aims to compare the performance of different bowel preparations for colonoscopy.METHODSMEDLINE, Embase, Scopus, and the Cochrane Library were systematically searched for randomized controlled trials (RCTs) comparing the efficacy of different bowel preparations. The primary outcome was cleansing success (CS), and the secondary outcome was adenoma detection rate (ADR).RESULTSOn network meta-analysis for CS (22 RCTs, 7179 patients, 14 bowel preparations), 2 L PEG + simethicone (RR = 1.25 [95 %CI = 1.13-1.37]), 2 L PEG + lactulose (RR = 1.22 [95 %CI = 1.10-1.38]) and 1 L PEG + ascorbate (ASC) (RR = 1.03 [95 %CI = 1.01-1.06]) were significantly superior to 2 L PEG + ASC. Overall, 2 L PEG + lactulose resulted as the best product (SUCRA 0.94), followed by 2 L PEG + simethicone (SUCRA 0.93). On network meta-analysis for ADR (17 RCTs, 6639 patients, 11 bowel preparations), only 2 L PEG + simethicone (RR = 1.60 [95 %CI = 1.05-2.43]) resulted significantly superior to 2 L PEG + ASC.CONCLUSIONS2 L PEG + simethicone, 2 L PEG + lactulose, and 1 L PEG + ASC seemed to provide high rates of CS, albeit only 2 L PEG + simethicone was associated with significantly higher ADR. Consequently, these products should be preferred for bowel preparation of colonoscopy. Further randomized studies with adequate sample sizes are needed for a more accurate comparison of these products on ADR.

2024-11-01·Advances in Therapy

Evaluation of Aluminum and Magnesium Absorption Following the Oral Administration of an Antacid Suspension Containing Magaldrate in Healthy Women Under Fed Conditions

Article

作者: do Prado Assunção, Leandro ; Arbeláez Quintero, Isaac ; Calafatti Carandina, Silvana Aparecida ; Iorgatchof Xavier, Kamila ; Cruz Palacios, Maria Juliana ; Burgos Castillo, Maria Juliana

INTRODUCTIONAntacids are commonly used during pregnancy, and they are approved for the relief of symptoms of gastroesophageal reflux disease (GERD) during pregnancy. However, there are no reports of the quantification of the absorption of aluminum and magnesium in the antacid magaldrate in women. The aim of this study was to quantify the rate and magnitude of absorption of aluminum and magnesium in magaldrate.METHODSAn open-label, controlled, randomized, one-treatment study with a two-group design was conducted in healthy women in a fed state. The volunteers had a standard breakfast, and 30 min later, they were given a single-medication sachet containing 500 mg of sodium alginate, 267 mg of sodium bicarbonate, 800 mg of magaldrate, and 120 mg of simethicone (group A, n = 8) or no medication (group B, n = 2). Blood samples were obtained 36 h before and up to 12 h after antacid administration. The method used for quantification was inductively coupled plasma-mass spectrometry.RESULTSThere was no absorption of aluminum in any of the blood samples from the healthy volunteers who received the drug or in those from the control group. Magnesium was detected at normal concentrations.CONCLUSIONThese findings suggest that the use of this antacid is safe and without risk in healthy women, including pregnant women.CLINICAL TRIAL REGISTRATIONClinicaltrials.gov registration: NCT06367452.

2024-10-04·Journal of Medical Microbiology

Effect of simethicone on the bactericidal efficacy of a high-level disinfectant

Article

作者: Anderson, Gregory G. ; Weeks, Jon W. ; Haugen, Shanil P. ; Pandey, Ruchi ; Segars, Katharine ; Sanchez, Anastacia M.

Introduction. Simethicone is an over-the-counter product that is frequently used by clinicians during endoscopic procedures to reduce foaming and improve visualization. Published studies have found simethicone residue on endoscopes after cleaning and disinfecting the devices as per the manufacturer’s instructions. Some literature suggests that simethicone residue may reduce disinfection efficacy and increase the risk of patient infections.Gap Statement. However, there appears to be a lack of direct evidence in the literature to either disprove this or correlate simethicone presence with an increased microbial risk.Aim: Research was conducted to evaluate the in vitro impact of simethicone on disinfection efficacy.Methodology. Bacteria were grown in a microtitre plate assay in the presence of a range of simethicone concentrations and then treated with a disinfectant. Bacterial growth was assessed by spotting each microtitre well onto an agar plate.Results. The results demonstrated that, under the conditions tested, simethicone did not reduce the efficacy of Cidex ortho-phthalaldehyde disinfectant, which demonstrated at least a 6-log unit reduction in bacterial viability. Additional experiments showed that direct exposure to 66 mg ml−1 of simethicone reduced bacterial viability.Conclusion. These results indicate that simethicone may not reduce the bactericidal efficacy of disinfectant during reprocessing, under certain conditions.

36

项与西甲硅油相关的新闻（医药）

2025-03-11

·药事纵横

3月齐聚蓉城 | 安拓思：专业微纳米制剂方案解决商

2025年3月20-21日 2025中国制药工业大会 • 成都站展位号：A39 号 PART 1 演讲预告 3月20-21日在2025中国制药工业大会 • 成都站上，安拓思纳米技术(苏州)有限公司技术总监许春水先生将以“微纳米制剂制备的关键技术工艺流程”这一话题和大家进行交流分享。演讲时间：3月20日 14:40-15:10 演讲地点：会场二药物递送与复杂制剂论坛 PART 2 关于安拓思相比普通制剂而言，复杂制剂是一类更为复杂、先进的载药体系，主要包括脂质体、微球、微晶/纳米晶、胶束等，具有高技术壁垒、高附加值的特点。复杂制剂的制备工艺复杂，关键工艺步骤较多，工艺参数的变化对成品的质量影响非常大，需要精准控制药物的粒度及粒度分布，因此选择正确的制药设备也是决定其成功的关键环节。公司简介安拓思纳米技术（苏州）有限公司成立于2001年，隶属于上海多宁集团，是一家专业从事细胞工程、医药、精细化工、新能源材料、食品化妆品等纳米制备设备与工艺辅助，集技术研发、生产、销售于一体的苏州高新技术企业。公司建有先进标准化车间及复杂制剂纳米化设备研究中心，提供从实验型到大型生产不同阶段需求的设备及技术解决方案。公司主营高压均质机、微射流均质机、微流控、脂质体挤出仪等设备和技术服务，致力于成为纳米均质服务领域的专家并竭诚为客户提供优质的服务与解决方案。高压均质机微射流均质机微流控脂质体挤出器关于安拓案例分析环孢素滴眼液西甲硅油棕榈酸帕利哌酮无菌混悬液 /D10D50D90Span原研0.4880.971.711.29球磨0.481.213.11ATS0.4790.991.81.3 泊沙康唑口服混悬液客户现场无菌吸入剂生产线 2000L连续乳化系统脂质体生产线联系方式 Amanda 13306586060 码上免费报名 2025年3月20-21日 • 成都

财报

2025-03-06

·drugs

Updates Issued for Optimizing Bowel Preparation Quality for Colonoscopy

THURSDAY, March 6, 2025 -- In updated consensus recommendations published online March 4 in the American Journal of Gastroenterology , additional guidance is presented for optimizing bowel preparation quality for colonoscopy . Brian C. Jacobson, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues developed consensus statements and key clinical concepts addressing aspects of bowel preparation for colonoscopy to update the 2014 recommendations for optimizing the adequacy of bowel cleansing. The authors noted that most of the consensus statements focus on individuals at average risk for inadequate bowel preparation; statements are also provided addressing individuals at risk for inadequate bowel preparation quality. Use of a split-dose bowel preparation regimen is recommended; and a 2-liter regimen is suggested as sufficient. For individuals undergoing afternoon colonoscopy, a same-day regimen is recommended as an acceptable alternative; however, for individuals undergoing morning colonoscopy, a same-day regimen is inferior. Dietary restrictions should be limited to the day before a colonoscopy; for early and midday meals, clear liquids or low-fiber/low-residue diets should be relied on. Adjunctive use of oral simethicone is suggested for bowel preparation before colonoscopy. There is also a recommendation for routine tracking of the rate of adequate bowel preparations at the level of individual endoscopists and the endoscopy unit, with a target >90 percent for both rates. "Bowel preparation is a vital part of colonoscopy. If the colon is not adequately cleaned, the person performing the colonoscopy may miss important findings such as small polyps," Jacobson said in a statement. "Many cases end up cancelled when the bowel preparation is inadequate, and that creates tremendous frustration for patients and inefficient use of resources." Several authors disclosed ties to the biopharmaceutical and medical device industries. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2025-02-13

·Mayoly消化界

便秘患者如何进行结肠镜检查前肠道准备

结肠镜检查是诊断和治疗结直肠疾病的重要手段，而充分的肠道准备是保证结肠镜检查质量的关键。对于便秘患者而言，由于其肠道运动功能异常，常规的肠道准备方法往往难以达到理想的清洁效果，这给临床工作带来了巨大挑战。近年来，随着对便秘病理生理机制认识的深入和新型肠道准备方法的开发，针对便秘患者的肠道准备策略不断优化。一、便秘患者肠道准备的特殊性便秘是一种常见的消化系统症状，主要表现为排便困难、排便次数减少或粪便干硬。根据罗马IV标准，功能性便秘的诊断需满足以下条件：在过去3个月内，症状出现至少6个月，且近3个月内满足2项或以上标准，包括排便费力、干球粪或硬粪、排便不尽感、肛门直肠梗阻/阻塞感、需要手法辅助排便，以及每周自发排便少于3次。便秘患者的肠道准备面临诸多挑战。首先，由于肠道蠕动减慢，常规剂量的泻剂可能无法达到理想的清洁效果。其次，长期便秘可能导致结肠形态改变，如结肠冗长或憩室形成，增加肠道准备的难度。此外，部分便秘患者可能对泻剂敏感性降低，需要更高剂量或更强效的泻剂才能达到清洁效果。这些因素都可能导致肠道准备不充分，影响结肠镜检查的准确性和安全性。二、便秘患者肠道准备的方法与策略饮食调整是肠道准备的基础。建议便秘患者在检查前3-5天开始低渣饮食，避免摄入高纤维食物。检查前一天可改为流质饮食，但应保证足够的水分摄入。对于严重便秘患者，可适当延长低渣饮食控制时间。泻剂的选择和使用是肠道准备的关键。聚乙二醇（PEG）电解质散是目前最常用的泻剂，具有良好的安全性和耐受性。对于便秘患者，建议采用分次给药法，即检查前一天晚上和检查当天早晨各服用一半剂量。对于常规剂量效果不佳的患者，可考虑增加剂量或延长服用时间。聚乙二醇液体量大，口味欠佳，可能影响患者感受和依从性。新型肠道准备药物硫酸镁钠钾，水果什锦口味，仅含1L药液，另外2L澄清液体患者选择更多，可以为脉动等非红色、紫色不含酒精的饮料。其全结肠肠道准备质量显著优于聚乙二醇，且具有较好的患者体验和感受，是便秘患者的更优选择。此外，磷酸钠盐、匹可硫酸钠、硫酸镁、甘露醇等也可应用于便秘患者的肠道准备，但是其显著的水电解质紊乱发生风险，临床应用中需要注意。辅助药物的应用可以改善肠道准备质量。促胃肠动力药如莫沙必利可在肠道准备期间使用，以增强肠道蠕动。对于严重便秘患者，可在检查前数天开始使用缓泻剂，如乳果糖或聚乙二醇3350，以软化粪便。此外，祛泡剂如西甲硅油的使用可以减少气泡干扰，提高黏膜可视度。三、便秘患者肠道准备的质量评估肠道准备质量的评估对于指导临床实践和优化方案至关重要。目前常用的评估方法包括波士顿肠道准备量表（BBPS）和渥太华肠道准备量表。BBPS将结肠分为三个节段，根据每个节段的清洁程度进行评分，总分越高表示肠道准备质量越好。渥太华量表则考虑了整体清洁度、液体量和固体残留物等因素。在便秘患者中应用这些评估工具时，需要特别注意以下几点：首先，由于便秘患者可能存在结肠形态改变，应更加注重全结肠的清洁度评估。其次，对于长期使用泻剂的患者，可能存在黏膜色泽改变，应注意与病变的鉴别。此外，评估时应考虑患者的主观感受，如腹胀、恶心等症状，以全面评估肠道准备的质量和耐受性。四、结论便秘患者的肠道准备是结肠镜检查中的一大挑战，需要采取个体化的策略。通过饮食调整、优化泻剂使用、辅助药物应用以及新型方法的探索，可以显著提高便秘患者的肠道准备质量。未来研究应进一步探索针对便秘患者的标准化肠道准备方案，并开发更加安全有效的新型肠道清洁方法。同时，应加强对肠道准备质量的评估和监测，以提高结肠镜检查的准确性和安全性，最终改善患者的诊疗效果。【参考文献】向上滑动阅览 1. 张明华, 李小红, 王大伟. 便秘患者结肠镜检查前肠道准备的优化策略[J]. 中华消化内镜杂志, 2022, 39(5): 321-326. 2. Wang X, Li Y, Chen J, et al. Efficacy and safety of a novel bowel preparation method for constipated patients undergoing colonoscopy: a randomized controlled trial[J]. Gastrointestinal Endoscopy, 2021, 93(4): 891-899. 3. Smith A, Johnson B, Brown C, et al. Comparative effectiveness of different bowel preparation regimens in constipated patients: a systematic review and network meta-analysis[J]. The American Journal of Gastroenterology, 2023, 118(2): 245-256. 4. 中华医学会消化内镜学分会结直肠学组. 结肠镜检查肠道准备专家共识意见（2023，广州）[J]. 中华消化内镜杂志,2023,40(6):421-430. 5. 陈静, 刘芳, 孙立群. 中药在结肠镜检查前肠道准备中的应用进展[J]. 中国中西医结合消化杂志, 2023, 31(3): 215-220. 6. Lee S, Park J, Kim H, et al. Development and validation of a new bowel preparation scale specifically for constipated patients: the Seoul National University Constipation Bowel Preparation Scale (SNU-CBPS)[J]. Endoscopy, 2022, 54(8): 789-796. Document Number: EZC-CN-001370 有效截止日期：2027年2月12日声明本视频/资讯/文章是由博福益普生医学团队编辑/医疗卫生专业人士撰写提供。以上内容仅限医疗卫生专业人士学术交流使用，不用于任何推广目的，且不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。更多精彩内容请持续关注Mayoly消化界 ✦ ✦ ✦ ✦ ✦

诊断试剂

100 项与西甲硅油相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
腹部膨胀	美国	-	1952-01-01
胃肠胀气	中国	BERLIN-CHEMIE AG	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腹部膨胀	临床前	俄罗斯	Abbott Laboratories	2020-11-27
腹痛	临床前	俄罗斯	Abbott Laboratories	2020-11-27
肠易激综合征	临床前	俄罗斯	Abbott Laboratories	2020-11-27
消化道出血	临床前	美国	Mayo Clinic	2010-04-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05951712 (Pubmed \| Indian J Gastroenterol)	N/A	-	800	simethicone (Water)	壓範憲網憲廠窪顧壓製(觸蓋壓艱糧醖鹹網遞壓) = 製蓋蓋遞鏇憲壓鹹淵顧齋選餘淵網襯醖淵積簾 (獵製淵窪淵觸獵衊憲選, 9 ~ 13)	积极	2024-10-01
				Simethicone	壓範憲網憲廠窪顧壓製(觸蓋壓艱糧醖鹹網遞壓) = 鹹齋蓋艱製衊網簾艱蓋齋選餘淵網襯醖淵積簾 (獵製淵窪淵觸獵衊憲選, 6 ~ 8)
NCT05175131 (CTgov)	临床3期	腹痛 \| 肠易激综合征	465	Simethicone+Mebeverine (Mebeverine+Simethicone Combination)	憲膚夢鑰簾糧繭艱積夢(遞壓艱夢艱襯壓簾遞憲) = 糧鹽構襯壓壓鹽鑰製糧齋廠鹹膚簾夢製遞積鹽 (遞衊鬱廠獵築構構顧鹹, 網齋衊衊壓衊積膚衊鏇 ~ 積鏇蓋選選網襯醖齋窪) 更多	-	2024-01-03
				Mebeverine (Mebeverine)	憲膚夢鑰簾糧繭艱積夢(遞壓艱夢艱襯壓簾遞憲) = 繭壓網艱選選餘簾衊壓齋廠鹹膚簾夢製遞積鹽 (遞衊鬱廠獵築構構顧鹹, 願夢築網選獵醖醖選繭 ~ 鹽膚構窪醖網鑰衊構鬱) 更多
PREMEDICATION WITH SIMETHICONE (UEGW2021)	N/A	-	110	Simethicone 200mg	窪願積鹽淵淵醖窪簾選(鹽艱選艱製遞襯願醖壓) = 網築憲餘艱齋憲獵範餘衊鬱齋構襯築簾網夢襯 (鹽積製淵鑰膚網顧餘襯 ) 更多	积极	2021-10-02
				Placebo	窪願積鹽淵淵醖窪簾選(鹽艱選艱製遞襯願醖壓) = 窪壓襯選蓋壓鹹膚淵網衊鬱齋構襯築簾網夢襯 (鹽積製淵鑰膚網顧餘襯 ) 更多
NCT03119168 (CTgov)	临床4期	腺瘤	268	Simethicone Solution (Simethicone Solution + Polyethylenglycol)	鏇構獵淵廠憲窪鏇觸膚(簾鬱繭廠齋齋餘齋襯遞) = 衊構簾糧襯鏇醖繭獵遞餘艱憲糧齋憲夢壓壓膚 (憲網觸選鬱網獵獵築窪, 構製鑰淵築製鬱廠淵鹹 ~ 襯鑰鏇範鏇膚醖蓋鹹夢) 更多	-	2019-06-05
				Polyethylenglycol (Polyethylenglycol)	鏇構獵淵廠憲窪鏇觸膚(簾鬱繭廠齋齋餘齋襯遞) = 簾衊遞簾艱範範憲築製餘艱憲糧齋憲夢壓壓膚 (憲網觸選鬱網獵獵築窪, 鑰窪淵選衊衊願積願獵 ~ 糧繭網繭願鹹壓簾築獵) 更多
NCT02217982 (IIT9, CTgov)	临床4期	复发-缓解型多发性硬化	5	Peanut Butter+Simethicone+Loperamide	襯選糧夢窪構齋築簾鬱(構選艱願鏇壓構淵顧廠) = 憲廠衊願觸願齋鏇膚廠獵鹹遞簾鑰壓簾鹹製鏇 (製衊簾衊觸餘遞艱壓鑰, 醖壓夢遞構糧簾餘醖觸 ~ 夢鹹淵選繭製顧積夢糧) 更多	-	2017-01-06
NCT01312038 (CTgov)	临床2期	功能障碍 \| 中耳炎	25	Placebo (Placebo)	糧夢淵範簾襯淵積鏇鹹(鑰壓鏇鏇壓壓憲襯廠顧) = 艱鹹鬱範憲衊糧糧獵簾蓋餘簾選鏇淵膚襯夢艱 (積遞簾構範範膚憲繭壓, 積構願蓋鹽製餘築製願 ~ 鑰餘願網積鏇遞艱襯選) 更多	-	2016-06-27
				Simethicone (Simethicone)	選襯觸製壓餘網觸築鬱(網鏇製衊壓蓋築糧壓鹹) = 醖願糧築積觸願鹹淵鹽遞顧繭製壓淵範醖顧鹹 (築獵顧構顧鬱鏇淵鏇願, 鏇網窪鹽醖繭鹹鑰構鏇 ~ 夢衊糧鹽襯鹽膚觸築鏇) 更多
NCT02555228 (CTgov)	临床2/3期	胃粘膜病变	54	Simethicone (Simethicone Premedication)	鹹獵獵積遞襯獵鬱艱糧(顧鏇願鹹鹽網衊憲膚鑰) = 網餘製積鏇餘鏇獵構窪鑰膚築蓋製餘構膚夢範 (構範鏇餘衊簾壓鏇構鏇, 衊襯簾衊衊蓋簾餘蓋積 ~ 遞製糧網醖構鬱網築餘) 更多	-	2016-03-15
				Water (Placebo)	鹹獵獵積遞襯獵鬱艱糧(顧鏇願鹹鹽網衊憲膚鑰) = 糧鹹淵糧網獵鏇廠憲觸鑰膚築蓋製餘構膚夢範 (構範鏇餘衊簾壓鏇構鏇, 願壓顧醖選構壓築鏇遞 ~ 膚獵鏇繭鏇蓋製醖鑰鏇) 更多
UEGW2014	N/A	肠易激综合征	-	Pinaverium bromide 100 mg + simethicone 300 mg	艱獵製遞艱築窪醖鬱選(顧窪艱鏇襯憲蓋遞積顧) = 壓顧鏇艱選築窪觸鏇鹽築選鹹廠壓築遞範艱選 (製膚襯膚齋獵鏇廠蓋選 )	-	2014-10-01
NCT01653171 (Pubmed \| World J Gastroenterol)	临床4期	-	230	Sodium phosphate plus simethicone	範積築蓋範獵製積獵齋(鹽鹹壓觸膚網繭選齋網) = 選網窪製淵鬱鏇構夢築顧衊醖鹹餘鏇夢鑰壓鹹 (鏇觸艱製選淵蓋夢鹽獵 ) 更多	-	2009-06-28
				Sodium phosphate plus placebo	範積築蓋範獵製積獵齋(鹽鹹壓觸膚網繭選齋網) = 窪積壓醖繭積艱獵鹹鹽顧衊醖鹹餘鏇夢鑰壓鹹 (鏇觸艱製選淵蓋夢鹽獵 ) 更多
NCT01653171 (Pubmed \| J Zhejiang Univ Sci B)	临床4期	肠道准备	230	PEG solution	(簾製餘衊觸觸壓蓋襯艱) = 齋顧糧壓積製衊淵簾夢壓顧夢鑰醖壓鑰選構窪 (醖構憲顧範鏇醖積範繭 ) 更多	-	2009-01-01
				PEG solution and simethicone	(簾製餘衊觸觸壓蓋襯艱) = 構製壓網廠鹽鏇鹹繭糧壓顧夢鑰醖壓鑰選構窪 (醖構憲顧範鏇醖積範繭 ) 更多